Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma

Erem, Cihangir; Koçak, Mustafa; Nuhoğlu, İrfan; Yılmaz, Mustafa; Ucuncu, Ozge

doi:10.1111/j.1365-2265.2009.03752.x

Cited by 68 publications

(62 citation statements)

References 42 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, decreased HDL cholesterol and increased TC and triglycerides have been reported in patients with prolactinomas as compared to healthy control subjects [61,62,63,64]. Similarly, total body fat percentage has been demonstrated to be increased in newly diagnosed treatment-naive hyperprolactinemic patients when compared to controls [44].…”

Section: Discussionmentioning

confidence: 99%

Effect of Cabergoline on Metabolism in Prolactinomas

Auriemma¹,

Granieri²,

Galdiero³

et al. 2013

Neuroendocrinology

View full text Add to dashboard Cite

Introduction: Hyperprolactinemia has been implicated in the pathogenesis of obesity and glucose intolerance and is reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of 12- and 60-month treatment with cabergoline (CAB) on metabolic syndrome (MetS) in patients with prolactinomas. Patients and Methods: 61 patients with prolactinomas (13 men, 48 women, 41 with microadenoma, 20 with macroadenoma), aged 34.4 ± 10.3 years, entered the study. In all patients, prolactin (PRL) and metabolic parameters were assessed at diagnosis and after 12 and 60 months of continuous CAB treatment. MetS was diagnosed according to NCEP-ATP III criteria. Results: Compared to baseline, CAB induced a significant decrease in PRL with complete normalization in 93% of patients after the 60-month treatment. At baseline, MetS prevalence was significantly higher in patients with PRL above (34.5%) than in those with PRL lower (12.5%) than the median (129 μg/l, p = 0.03). MetS prevalence significantly decreased after 12 (11.5%, p = 0.039) and 60 (5.0%, p = 0.001) months compared to baseline (28.0%). At both evaluations the lipid profile significantly improved compared to baseline. Fasting insulin and homeostatic model assessment of insulin resistance significantly decreased after 1 year of CAB (p = 0.012 and p = 0.002, respectively) and further improved after 60 months (p = 0.000). The visceral adiposity index significantly decreased after the 60-month treatment (p = 0.000) compared to baseline. At the 5-year evaluation CAB dose was the best predictor of percent decrease in fasting insulin (t = 2.35, p = 0.022). Conclusions: CAB significantly reduces MetS prevalence and improves the adipose tissue dysfunction index. The improvement in PRL, insulin sensitivity and other metabolic parameters might reflect the direct effect of CAB.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Cabergoline on Metabolism in Prolactinomas

Auriemma¹,

Granieri²,

Galdiero³

et al. 2013

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Indeed, decreased HDL and increased CHOL and TG have been reported in patients with prolactinomas as compared to controls [75,76,77,78], and a direct correlation between lipid metabolism and PRL levels has been proposed [48]. PRL can directly act on adipose tissue and may be involved in the lipid metabolism of mature adipocytes [79,80,81,82]. Moreover, D 2 R is also expressed on human adipocytes, suggesting a regulatory role for peripheral dopamine in adipose functions [83].…”

Section: Discussionmentioning

confidence: 99%

Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas

et al. 2015

View full text Add to dashboard Cite

Introduction: Hyperprolactinemia and hypogonadism are reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of testosterone replacement and cabergoline (CAB) treatment on the metabolic profile in male hyperprolactinemic patients. Patients and Methods: Thirty-two men with prolactinomas, including 22 with total testosterone (TT) <8 nmol/l (HG, 69%) and 10 with TT >8 nmol/l (non-HG, 31%), were entered in the study. In all patients, metabolic parameters were assessed at diagnosis and after 12- and 24-month treatment. Results: Compared to non-HG patients, at baseline the HG patients had higher waist circumference (WC). TT significantly correlated with body mass index (BMI). Twelve-month CAB induced PRL normalization in 84%. HG prevalence significantly decreased (28%) and non-HG prevalence significantly increased (72%). Anthropometric and lipid parameters, fasting insulin (FI), insulin sensitivity index (ISI₀), homeostatic model assessment of insulin secretion (HOMA-β) and homeostatic model assessment of insulin resistance (HOMA-IR) significantly improved compared to baseline. TT was the best predictor for FI. Percent change (Δ) of TT significantly correlated with ΔCholesterol, ΔWeight and ΔBMI. Compared to non-HG patients, the HG patients had a higher weight, BMI, WC and HOMA-β. In HG, testosterone replacement was started. After 24 months, PRL normalized in 97%. HG prevalence significantly decreased (6%) and non-HG prevalence significantly increased (94%). Anthropometric and lipid parameters, FI, ISI₀, HOMA-β and HOMA-IR significantly improved compared to baseline, with FI, ISI₀, HOMA-β and HOMA-IR further ameliorating compared to the 12-month evaluation. Compared to non-HG patients, the HG patients still had a higher weight, BMI and WC. Conclusions: In hyperprolactinemic hypogonal men, proper testosterone replacement induces a significant improvement in the metabolic profile, even though the amelioration in the lipid profile might reflect the direct action of CAB.

show abstract

“…In the same study, while platelet count, fibrinogen, tissue plasminogen activator inhibitor-1 (PAI-1) were increasing, plasma tissue factor pathway inhibitor (TFPI) level was detected decreased. It was suggested that this condition might contribute to an increased risk of atherosclerotic and atherothrombotic complications (21).…”

Section: Discussionmentioning

confidence: 99%

Mean platelet volume in patients with prolactinoma

Tam

Kaya

Başer

et al. 2016

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: Prolactin is a multifunctional pituitary hormone. The effect of prolactin on platelet activation is not well understood. Prolactinomas are the most common type of pituitary adenomas, and they are medically responsive to dopamine agonists. Mean platelet volume (MPV) is a marker of platelet function and activation. The aim of this study was to evaluate MPV values before and 6 months of cabergoline treatment when normoprolactinemia was achieved. Subjects and methods: A total of 101 newly diagnosed prolactinoma patients and 102 healthy control subjects were included in the study. Patients with hematological disorders that affect MPV and those on medications were excluded. Prolactin, platelet count and MPV levels were recorded before and 6 months after the initiation of cabergoline treatment (0.5 to 1 mg, two times a week). Results: There was no significant difference in platelet count and MPV before and after 6 months of treatment with cabergoline in patients with prolactinoma compared with the control group (p > 0.05). Conclusion: Our results showed that MPV, a marker of platelet function, was unchanged in patients with prolactinoma. Arch Endocrinol Metab. 2016;60(4):319-22

show abstract

Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma

Cited by 68 publications

References 42 publications

Effect of Cabergoline on Metabolism in Prolactinomas

Effect of Cabergoline on Metabolism in Prolactinomas

Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas

Mean platelet volume in patients with prolactinoma

Contact Info

Product

Resources

About